Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial

Ching Lam, Wei Tan, Matthew Leighton, Margaret Hastings, Melanie Lingaya, Yirga Falcone, Xiaoying Zhou, Luting Xu, Peter Whorwell, Andrew F Walls, Abed Zaitoun, Alan Montgomery and Robin C Spiller
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial

Ching Lam,¹ Wei Tan,² Matthew Leighton,² Margaret Hastings,³ Melanie Lingaya,¹ Yirga Falcone,¹ Xiaoying Zhou,⁴ Luting Xu,⁵ Peter Whorwell,³ Andrew F Walls,⁴ Abed Zaitoun,⁶ Alan Montgomery² and Robin C Spiller¹*

¹National Institute for Health Research (NIHR) Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust, Nottingham, UK
²Clinical Trials Unit, University of Nottingham, Nottingham, UK
³Neurogastroenterology Unit, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
⁴Immunopharmacology Group, University of Southampton, Southampton, UK
⁵FRAME Laboratory, University of Nottingham, Nottingham, UK
⁶Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, UK

*Corresponding author

Declared competing interests of authors: none

Published March 2015
DOI: 10.3310/eme02020

This report should be referenced as follows:

Criteria for inclusion in the Efficacy and Mechanism Evaluation journal

Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting ‘science driven’ studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: http://www.nets.nihr.ac.uk/programmes/eme

This report

The research reported in this issue of the journal was funded by the EME programme as project number 09/20/16. The contractual start date was in October 2010. The final report began editorial review in May 2014 and was accepted for publication in December 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, MRC, NETSCC, the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2015. This work was produced by Lam et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Efficacy and Mechanism Evaluation Editor-in-Chief

Professor Raj Thakker  May Professor of Medicine, Nuffield Department of Medicine, University of Oxford, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk
Abstract

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial

Ching Lam,1 Wei Tan,2 Matthew Leighton,2 Margaret Hastings,3 Melanie Lingaya,1 Yirga Falcone,1 Xiaoying Zhou,4 Luting Xu,5 Peter Whorwell,3 Andrew F Walls,4 Abed Zaitoun,6 Alan Montgomery2 and Robin C Spiller1*

1National Institute for Health Research (NIHR) Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust, Nottingham, UK
2Clinical Trials Unit, University of Nottingham, Nottingham, UK
3Neurogastroenterology Unit, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
4Immunopharmacology Group, University of Southampton, Southampton, UK
5FRAME Laboratory, University of Nottingham, Nottingham, UK
6Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, UK

*Corresponding author robin.spiller@nottingham.ac.uk

Background: Diarrhoea-predominant irritable bowel syndrome (IBS-D) is a common outcome after inflammation due to bacterial gastroenteritis. Several studies have shown ongoing immune activation in the mucosa of patients with IBS-D and a number of studies have suggested that mesalazine slow-release granule formulation (2 g; PENTASA®, Ferring Pharmaceuticals Ltd) may provide benefit including a reduction in stool frequency.

Objectives: Our primary aim was to compare the effect of mesalazine with placebo on stool frequency. Our secondary aims were to assess the effect of mesalazine on abdominal pain, stool consistency, urgency and satisfactory relief of irritable bowel syndrome (IBS) symptoms.

Design/participants/intervention: We performed a double-blind, randomised placebo-controlled trial of 2 g mesalazine twice daily compared with placebo for 3 months in Rome III criteria patients with IBS-D.

Settings: Participants were recruited from the primary care research network and secondary care hospitals. Participants were randomised after a 2-week baseline stool diary. All participants completed a 12-week stool diary and at the end of each week recorded the presence of ‘satisfactory relief of IBS symptoms’. Those recruited in Nottingham had sigmoid biopsies and/or magnetic resonance imaging of the abdomen at the start and end of the trial.

Results: A total of 136 patients with IBS-D (82 female, 54 male) were randomised; 10 patients withdrew from each group. Analysis by intention to treat showed that the mean daily average stool frequency during weeks 11 and 12 was 2.8 (standard deviation (SD) 1.2) in the mesalazine group and 2.7 (SD 1.9) in the placebo group, with a group difference of 0.1 (95% confidence interval –0.33 to 0.53); p = 0.66.
Conclusions: Mesalazine did not improve abdominal pain, stool consistency or percentage with satisfactory relief compared with placebo during the last 2 weeks’ follow-up. A post hoc analysis in 13 postinfectious patients with IBS appeared to show benefit but this needs confirmation in a larger group. More precise subtyping based on underlying disease mechanisms may allow more effective targeting of treatment in IBS.

Trial registration: Current Controlled Trials ISRCTN76612274.

Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a MRC and NIHR partnership.
Contents

List of tables ix
List of figures xi
List of abbreviations xiii
Plain English summary xv
Scientific summary xvii

Chapter 1 Background
Existing research 1
Importance of mast cells in generating irritable bowel syndrome symptoms 1
Previous studies of mast cell stabilisers and anti-inflammatory agents in irritable bowel syndrome 2
Previous studies of mesalazine treatment for irritable bowel syndrome 2
Risk and benefits 2
Rationale for the current study 3

Chapter 2 Trial/study purpose and objectives
Purpose 5
Primary objective 5
Secondary objectives 5

Chapter 3 Trial/study design
Trial/study configuration 7
Randomisation and blinding 7
Participants 7
Recruitment 7
Inclusion criteria 8
Exclusion criteria 10
Expected duration of participant participation 10
Removal of participants from therapy or assessments 10

Chapter 4 Main outcome measures
Clinical outcomes 11
Primary outcome 11
Secondary outcomes (all assessed during weeks 11–12 of the treatment period) 11
Mechanistic outcomes 11
Primary outcome 11
Secondary outcomes 11

Chapter 5 Sample size 13
<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>TABLE 1</td>
<td>Patient visits and contacts</td>
<td>9</td>
</tr>
<tr>
<td>TABLE 2</td>
<td>Summary of recruitment by site and by treatment arm</td>
<td>20</td>
</tr>
<tr>
<td>TABLE 3</td>
<td>Summary of baseline data by treatment group</td>
<td>20</td>
</tr>
<tr>
<td>TABLE 4</td>
<td>Clinical primary outcome of daily mean stool frequency at weeks 11–12</td>
<td>21</td>
</tr>
<tr>
<td>TABLE 5a</td>
<td>Primary analysis of average stool frequency with further adjustment of baseline covariates</td>
<td>21</td>
</tr>
<tr>
<td>TABLE 5b</td>
<td>Primary analysis of average stool frequency with multiple imputation</td>
<td>21</td>
</tr>
<tr>
<td>TABLE 5c</td>
<td>Primary analysis of average stool frequency (CACE)</td>
<td>21</td>
</tr>
<tr>
<td>TABLE 6a</td>
<td>Primary outcome subgroup analysis by baseline stool frequency</td>
<td>21</td>
</tr>
<tr>
<td>TABLE 6b</td>
<td>Primary outcome subgroup analysis by baseline abdominal pain score</td>
<td>22</td>
</tr>
<tr>
<td>TABLE 6c</td>
<td>Primary outcome subgroup analysis by baseline HADS score</td>
<td>22</td>
</tr>
<tr>
<td>TABLE 7</td>
<td>Secondary outcome results</td>
<td>23</td>
</tr>
<tr>
<td>TABLE 8</td>
<td>Summary of compliance with trial medication (participants who completed 12 weeks of treatment)</td>
<td>24</td>
</tr>
<tr>
<td>TABLE 9</td>
<td>Effect of mesalazine vs. placebo on mast cell percentage area stained/m² in patients with IBS-D [median (IQR)]</td>
<td>26</td>
</tr>
<tr>
<td>TABLE 10</td>
<td>Baseline supernatant levels (ng/ml) between HVs and patients with IBS-D [median (IQR)]</td>
<td>27</td>
</tr>
<tr>
<td>TABLE 11</td>
<td>Supernatant mediator levels (ng/ml) following treatment with mesalazine or placebo [median (IQR)]</td>
<td>27</td>
</tr>
<tr>
<td>TABLE 12</td>
<td>Fasting small bowel water content (ml) following treatment with either mesalazine or placebo</td>
<td>30</td>
</tr>
<tr>
<td>TABLE 13</td>
<td>Faecal trypsin levels (trypsin units/mg protein) following treatment with mesalazine or placebo</td>
<td>31</td>
</tr>
<tr>
<td>TABLE 14</td>
<td>Summary of antibodies used in immunohistochemistry</td>
<td>51</td>
</tr>
<tr>
<td>TABLE 15</td>
<td>Adverse events following randomisation</td>
<td>52</td>
</tr>
<tr>
<td>TABLE 16</td>
<td>Recruitment into study (n)</td>
<td>53</td>
</tr>
</tbody>
</table>
LIST OF TABLES

TABLE 17 Recruitment for each site (n) 55

TABLE 18 Summary of number of days with stool diary entered at baseline and 11–12 weeks 61
List of figures

FIGURE 1 Patient flow chart (CONSORT diagram) 19

FIGURE 2 Mast cell count assessed from percentage area stained comparing healthy control subjects and patients with IBS-D (median, IQR) 25

FIGURE 3 Effect of mesalazine vs. placebo on mast cell percentage area stained in patients with IBS-D (median, IQR) 26

FIGURE 4 Baseline CPA3 levels in patients with IBS-D 27

FIGURE 5 Tryptase levels before and after treatment with mesalazine or placebo (median, IQR) 28

FIGURE 6 Chymase levels before and after treatment with mesalazine or placebo (median, IQR) 28

FIGURE 7 Carboxypeptidase A3 levels before and after treatment with mesalazine or placebo (median, IQR) 29

FIGURE 8 Histamine levels before and after treatment with mesalazine or placebo (median, IQR) 29

FIGURE 9 Serotonin levels before and after treatment with mesalazine or placebo (median, IQR) 30

FIGURE 10 Fasting small bowel water before and after treatment with mesalazine or placebo (median, IQR) 31

FIGURE 11 Changes in fasting small bowel water before and after treatment with either mesalazine or placebo 31

FIGURE 12 Change in faecal tryptase following treatment with mesalazine compared with placebo (median, IQR) 32

FIGURE 13 CD3+ T lymphocyte count before and after treatment with mesalazine or placebo (median, IQR) 33

FIGURE 14 Correlation between baseline calprotectin levels (µg/g) and baseline total HADS score 33

FIGURE 15 Baseline stool calprotectin levels when divided into two groups (median, IQR) 34

FIGURE 16 Abdominal pain severity before and after treatment with mesalazine or placebo 34

FIGURE 17 Urgency symptoms before and after treatment with mesalazine or placebo 35
LIST OF FIGURES

FIGURE 18  Stool consistency before and after treatment with mesalazine or placebo  35

FIGURE 19  Total recruitment by date  54

FIGURE 20  Recruitment by site and date  56
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-ASA</td>
<td>5-aminosalicylic acid</td>
</tr>
<tr>
<td>5-HT</td>
<td>serotonin</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>BSFS</td>
<td>Bristol Stool Form Scale</td>
</tr>
<tr>
<td>CACE</td>
<td>Complier Average Causal Effect</td>
</tr>
<tr>
<td>CD3</td>
<td>CD3+ T lymphocytes</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CONSORT</td>
<td>Consolidated Standards of Reporting Trials</td>
</tr>
<tr>
<td>CPA3</td>
<td>carboxypeptidase A3</td>
</tr>
<tr>
<td>CTU</td>
<td>Clinical Trials Unit</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EOT</td>
<td>end of trial</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>European Quality of Life-5 Dimensions</td>
</tr>
<tr>
<td>HADS</td>
<td>Hospital Anxiety and Depression Scale</td>
</tr>
<tr>
<td>HV</td>
<td>healthy volunteer</td>
</tr>
<tr>
<td>IBS</td>
<td>irritable bowel syndrome</td>
</tr>
<tr>
<td>IBS-D</td>
<td>diarrhoea-predominant irritable bowel syndrome</td>
</tr>
<tr>
<td>IL-1β</td>
<td>interleukin-1 beta</td>
</tr>
<tr>
<td>IMP</td>
<td>investigational medicinal product</td>
</tr>
<tr>
<td>IQR</td>
<td>interquartile range</td>
</tr>
<tr>
<td>ITT</td>
<td>intention to treat</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>PCRN</td>
<td>Primary Care Research Network</td>
</tr>
<tr>
<td>PHQ-15</td>
<td>Patient Health Questionnaire 15</td>
</tr>
<tr>
<td>PI-IBS</td>
<td>postinfective irritable bowel syndrome</td>
</tr>
<tr>
<td>SD</td>
<td>standard deviation</td>
</tr>
<tr>
<td>SSRI</td>
<td>selective serotonin reuptake inhibitor</td>
</tr>
<tr>
<td>TCA</td>
<td>tricyclic antidepressant</td>
</tr>
<tr>
<td>TNF</td>
<td>tumour necrosis factor</td>
</tr>
<tr>
<td>TNF-α</td>
<td>tumour necrosis factor alpha</td>
</tr>
</tbody>
</table>
Plain English summary

Irritable bowel syndrome (IBS) is a chronic condition characterised by abdominal pain or discomfort and irregular bowel habit, which has many causes involving an interaction between the gut and brain. Mast cells in the gut lining which can be activated by allergy or stress are thought to be important in causing symptoms in some patients with IBS because they can release chemicals that cause pain and diarrhoea. Currently, there are few effective treatments available to alleviate these symptoms. Recent small studies have shown that mesalazine, an ‘anti-inflammatory’ drug, may be able to modify and reverse the symptoms of IBS with diarrhoea. One small study suggested that mesalazine reduced mast cell numbers. This current study is one of the largest studies looking at the use of mesalazine as a form of treatment for IBS with diarrhoea. Unfortunately, this study did not show any beneficial effect of mesalazine treatment in unselected patients with IBS and diarrhoea. Potentially, there is a subgroup of patients with IBS who developed their symptoms following a bout of gastroenteritis and who appeared to benefit from mesalazine treatment, but a larger study is needed to confirm this. We did not find that the mast cell mediators released from mucosal biopsies were useful markers of disease, as they failed to correlate with any symptoms.
Scientific summary

Background

Irritable bowel syndrome (IBS) is a heterogeneous condition, characterised by abdominal pain/discomfort and disturbed bowel habit. There is an interaction between gut pathology and disturbed central processing of visceral afferent signalling in this group of patients. Patients may suffer from both diarrhoea (with accelerated transit) and constipation (when transit is delayed), with around one-third of them having a mixed bowel pattern with episodes of both diarrhoea and constipation. Both subtypes exhibit hypersensitivity to rectal distension. Although the majority of patients with IBS have mild symptoms and are commonly managed in the community, there is a small proportion of patients who have moderate to severe symptoms, who are referred to secondary care for further investigations and management of their symptoms. Most treatments are based on symptom control rather than a ‘cure’, owing to lack of understanding of the underlying mechanisms. However, there have recently been reports of ‘immune activation’ in the mucosa of patients with diarrhoea-predominant irritable bowel syndrome (IBS-D), such as increased mast cell numbers and release of proinflammatory mediators, for example tryptase and histamine. This has been supported by animal studies that clearly show mast cell activation by psychological stress, associated with the development of visceral hypersensitivity, a key feature of IBS in humans. Although some reports have linked severity of pain to the number of mast cells in close proximity to nerves, a link between symptoms and mast cell numbers or mediators released from mucosal biopsies has not been seen in recent mechanistic studies. Other human studies have reported increased in immune cells, such as T lymphocytes and enterochromaffin cells, particularly in postinfectious IBS. There have been three small pilot randomised placebo-controlled trials and one open-labelled study suggesting that mesalazine slow-release granule formulation (2 g; PENTASA®, Ferring Pharmaceuticals Ltd), 5-aminosalicylic acid (5-ASA), may improve symptoms of IBS, such as abdominal pain and improvement in bowel habit, particularly in patients with postinfective irritable bowel syndrome (PI-IBS). One small study with just 20 patients showed a reduction in mast cell numbers following treatment.

Objectives

Our clinical primary outcome was to compare the effect of mesalazine with placebo on stool frequency. Secondary clinical outcomes were to assess the effect of mesalazine on abdominal pain, stool consistency, urgency and satisfactory relief of IBS symptoms. The primary mechanistic outcome was to assess change in mast cell percentage area stained after treatment with mesalazine. Secondary mechanistic outcomes were to assess mast cell tryptase release, volume of fasting small bowel water, faecal tryptase and calprotectin.

Methods

All participants met the modified Rome III criteria for IBS-D. Organic diseases were excluded with normal blood tests and sigmoidoscopy/colonoscopy. Participants taking non-steroidal anti-inflammatory drugs or 5-ASA compounds were excluded from the study. All participants were randomised after a 2-week baseline stool diary. All participants completed a 12-week stool diary and at the end of each week they recorded the presence of ‘satisfactory relief of IBS symptoms’.
Results

Our large multicentred, parallel group, randomised placebo-controlled trial of mesalazine for treatment of IBS-D, which randomised 136 subjects, was powered to detect a significant difference in bowel frequency but has shown no clinical benefit over placebo in patients with IBS-D. Mechanistic assessments showed no significant changes in mast cell numbers or mast cell mediators released from mucosal biopsies. We did not find that the rate of release of mast cell products from a colonic biopsy was a useful biomarker, as it failed to correlate with any symptoms. Mesalazine did not cause significant changes in fasting small bowel water content, faecal tryptase or calprotectin. There was, however, a small number ($n = 13$) of patients with IBS-D who met the criteria for PI-IBS and who showed significant clinical benefit of treatment with mesalazine. This requires confirming in a further larger and more adequately powered study.

Conclusion

This study does not support any clinically meaningful benefit or harm of mesalazine compared with placebo in unselected IBS with diarrhoea. If there is a subgroup that benefits it is likely to be those with postinfective IBS and a trial of such patients, particularly those with more severe diarrhoea. Therefore, a more precise subtyping based on underlying disease mechanisms is needed to allow more effective targeting of treatment in IBS.

Trial registration

This trial is registered as ISRCTN76612274.

Funding

This project was funded by the Efficacy and Mechanism Evaluation (EME) Programme, a MRC and NIHR partnership.
Chapter 1 Background

Existing research

Irritable bowel syndrome (IBS) is one of the commonest conditions seen by gastroenterologists, experienced by 1 in 10 of the population at some time in their lives and accounting for up to 40% of new referrals to gastroenterology outpatient departments. The condition is characteristically heterogeneous but all patients have abdominal discomfort and disturbed bowel habit. The other feature found in at least half of patients with IBS is a history of anxiety or depression, and the presence of multiple unexplained physical symptoms, otherwise known as ‘physical symptom disorder’ or ‘somatisation’, is present in two-thirds of patients. Patients often believe that stress aggravates their symptoms but the effect does not appear to be immediate, as there is a poor correlation between stress and symptoms on a day-to-day basis. The effect appears to be more long term and patients with chronic stressors rarely recover until these are relieved. In animals, chronic stress causes diarrhoea, an effect that appears to be mediated through the release of corticotropin-releasing factor within the brain, where it activates descending autonomic pathways, delaying gastric emptying and accelerating colonic transit. Corticotropin-releasing factor is also found locally in the mucosa, where its release may activate mast cells. In addition to these effects of acute stress, chronic stress in experimental animals, generated by repetitive water avoidance or lifelong stress following maternal deprivation in the neonatal period, increases the number of mast cells within the mucosa. This leads to increased gut permeability and increased translocation of bacteria with associated low-grade immune activation within the mucosa.

More recently, evidence has been accumulating that similar activation of mast cells can occur in stressed humans. Acute stress induced by immersion of the hand into ice-cold water has been shown to stimulate jejunal water secretion and the release of mast cell products, including tryptase and histamine, in healthy volunteers (HVs). In patients with diarrhoea-predominant irritable bowel syndrome (IBS-D), mast cell numbers have been shown to be increased in jejunal biopsies, along with intraepithelial CD3+ T lymphocytes (CD3). This study also showed higher tryptase concentration in aspirated jejunal fluid, suggesting that the mast cells were activated, and more recent studies show that the ensuing increase in gut permeability is confined to females, suggesting an important gender difference in susceptibility to stress-induced gut changes, which accords with the known female predominance of IBS. We have recently confirmed increased numbers of mast cells and intraepithelial lymphocytes in duodenal biopsies from patients with IBS-D in Nottingham, who also show increased tryptase release into the supernatants of incubated duodenal biopsies.

Importance of mast cells in generating irritable bowel syndrome symptoms

There are numerous reports now of increased mast cell numbers in patients with IBS, in the terminal ileum, caecum and rectum. Mast cells contain many mediators, including histamine, serotonin (5-HT) and tryptase. Recent interest has focused on the tryptase content because it has been shown to activate protease-activated receptor 2 (PAR2) receptors, which are found on afferent nerves, and their activation increases sensitivity of the bowel to distension. Supernatants from IBS mucosal biopsies have been shown to activate afferent nerves in an isolated mouse jejunal segment, and, more recently, in human colonic submucosal nerves. We propose that anxiety and chronic stressors act in humans to increase the number of activated mast cells throughout the gut in patients with IBS, thereby inducing the characteristic visceral hypersensitivity and abdominal pain. We hypothesised that mesalazine slow-release granule formulation (2 g; PENTASA®, Ferring Pharmaceuticals Ltd) treatment, through its anti-inflammatory effects, would reduce the number of mast cells and thereby reduce abdominal pain, stool looseness and stool frequency.
Previous studies of mast cell stabilisers and anti-inflammatory agents in irritable bowel syndrome

Although there were some poorly designed trials two decades ago, claiming to show that sodium cromoglycate was effective for IBS,16–18 these studies remain unconfirmed and the treatment is not widely used. There have been other smaller studies targeting mast cells with antihistamines, such as ketotifen;19 although this reduced visceral hypersensitivity, it had no effect on mast cell numbers or release of mast cell mediators. Our own trial of prednisolone in postinfective IBS (PI-IBS) was of limited duration – just 3 weeks – and, although this showed a halving of CD3, patient symptoms were already subsiding and we were not able to show any difference from the control subjects. In that study, the fall in mast cell numbers on prednisolone was twice that on placebo but this difference was not statistically significant. We felt that 3 weeks was too short a time period to make an impact on mucosal histology. A strategy that reduced mast cell numbers over the long term might well be more effective than specific inhibitors of mast cell activation, or indeed any specific mast cell products, as these are numerous [histamine, tumor necrosis factor (TNF), prostaglandin, substance P, mast cell tryptase and nerve growth factor (NGF)], all with quite variable modes of action.

Previous studies of mesalazine treatment for irritable bowel syndrome

The first anecdotal open-label trial of 12 patients with resistant IBS-D who responded to mesalazine20 showed a benefit that took about 2–3 months to become apparent. There have since been two further reports of open-label treatment21,22 and two small randomised controlled trials.23,24 All but the Corinaldesi et al.23 trial used patients with IBS-D. The Bafutto et al. trial22 used mesalazine 800 mg three times a day for 30 days in 61 patients with IBS-D – 18 of whom had PI-IBS and showed benefit with a reduction in stool frequency, stool consistency and abdominal pain – but was uncontrolled, with no placebo arm. The Andrews et al. study21 involved just six patients but this showed that mesalazine decreased biopsy proteolytic activity. Both of the randomised controlled trials23,24 are rather too small for their significance to be sure, with n = 20 and n = 17, respectively. One study23 showed a significant reduction of mast cell numbers and an overall reduction in inflammatory cells.

Risk and benefits

Mesalazine has been widely used for > 45 years and there are extensive data on its side effects. In general, the drug is well tolerated. Nephrotoxicity is seen at a rate of about 1 per 100,000 prescriptions;25 commoner, but less serious, side effects include diarrhoea, nausea, vomiting and abdominal pain, together with headaches, pancreatitis and blood disorders, which are all rare. Balancing this, patients with IBS suffer a marked decrease in quality of life, similar to that of other chronic diseases such as diabetes and heart failure. They also spend significant amounts of time off work and when they are at work they work less efficiently. A simple safe and effective treatment would be of undoubted benefit to what is a substantial subgroup of the population, given that IBS-D affects around 3% of the general population.
Rationale for the current study

Studies in Nottingham over the last decade have identified the importance of inflammation in various subgroups of IBS. We have focused on the group of patients with IBS who develop symptoms following acute bacterial gastroenteritis, the so-called postinfectious IBS. In this group, we have been able to show that the acute inflammatory insult associated with acute Campylobacter jejuni enteritis is followed by a more prolonged indolent phase with increased chronic inflammatory cells long after the infecting organism has left the body. In this subgroup of IBS we have demonstrated activated circulating peripheral blood mononuclear cells with increased cytokine production and an associated increase in inflammatory gene expression. We have also demonstrated the importance of anxiety and depression, which, along with adverse life events, increase the risk of PI-IBS. The changes observed in PI-IBS are similar to those in IBS-D, the predominant bowel disturbance being diarrhoea with a similar prognosis. This work has been supported by others who have shown inflammatory changes in patients with IBS-D who do not have a background of previous infection. Such studies have also shown increased inflammatory cells and increased expression of inflammatory cytokines, including interleukin-1 beta (IL-1β). Increased gut permeability has also been shown in IBS-D, making a trial of an anti-inflammatory treatment a logical choice. Safety is of pre-eminent importance with IBS drugs, as can be seen by the recent withdrawal of tegaserod (Zelnorm®, Novartis) and the previous withdrawal of alosetron (Lotronex®, Prometheus). Both drugs, which were therapeutically effective, had to be withdrawn as a result of rare side effects (incidence < 1 per 700 patients treated). This leaves such patients bereft of effective treatments, a gap that mesalazine might well fill. Our hypothesis was that mesalazine, by virtue of its anti-inflammatory actions, would alter the inflammatory mediators leading, over a number of weeks, to a reduction in the number of mast cells and a reduction in the release of inflammatory mediators, and hence to a reduction in symptoms. Previous studies have shown that 5-aminosalicylic acid (5-ASA) inhibits the release of inflammatory mediators, including histamine and prostaglandin D₂. It also inhibits activation of the transcription factor ‘nuclear factor kappa-light-chain-enhancer’ of activated B cells, which is a major link in the inflammatory cascade. More recently, it has been recognised that 5-ASA exerts an anti-inflammatory effect that is mediated via peroxisome proliferator-activated receptor gamma (PPARγ receptors). Whether directly or indirectly, 5-ASA has also been reported to inhibit inducible nitric oxide synthetase production and also prostaglandin production via its cyclooxygenase-2 inhibitory effects. Mesalazine, therefore, both by virtue of inhibiting other inflammatory pathways and by directly inhibiting mast cell pathways, may reduce mucosal immune activation. We plan to investigate the effect of long-term mesalazine on mast cell numbers, the chronic inflammatory cells and the mucosal production of inflammatory cytokines, IL-1β and tumour necrosis factor alpha (TNF-α) as well as mast cell-specific tryptase. We also examined its effect on stool calprotectin, a marker of colonic inflammation, which is widely used to exclude inflammatory bowel disease and is also recognised to be modestly elevated in around 25% of most IBS series.
Chapter 2  Trial/study purpose and objectives

Purpose

The purpose of the trial was to define the clinical benefit and possible mediators of the benefit of mesalazine in IBS-D.

We therefore evaluated symptoms (primarily bowel frequency) and objective biomarkers reflecting mast cell activation and small bowel tone.

Primary objective

Effect of mesalazine on stool frequency in weeks 11 and 12.

Secondary objectives

Effect of mesalazine on the following:

1. overall IBS symptoms
2. mast cell numbers, mucosal lymphocytes and faecal tryptases
3. small bowel tone by measurement of fasting small bowel water content through magnetic resonance imaging (MRI).

Our overall aim was to assess the ability of the biomarkers listed above to predict treatment response.
Chapter 3 Trial/study design

Trial/study configuration

This was a multicentre, two-arm, parallel-group, double-blind randomised placebo-controlled trial comparing mesalazine with placebo in patients with IBS-D. The design of the study was modified after consultation with a selection of interested patients from the Nottingham Digestive Diseases Biomedical Research Unit patient advisory group, who provided a lay member for the Trial Steering Committee (TSC).

Randomisation and blinding

This was a double-blind, parallel-group study. The participant, supervising doctor and study nurse were not aware of the treatment allocation.

The randomisation was based on a computer-generated pseudo-random code using random permuted blocks of randomly varying size, created by the Nottingham Clinical Trials Unit (CTU) in accordance with their standard operating procedure (SOP), and held on a secure server. The randomisation was stratified by the recruiting centre. The supervising doctor or study nurse obtained a randomisation reference number for each participant by means of a remote, internet-based randomisation system that was developed and maintained by the Nottingham CTU.

The sequence and decode of treatment allocations were concealed until all interventions were assigned, recruitment, data collection and all other trial-related assessments were complete, and data files were locked.

Participants

Recruitment

Participants were recruited between April 2011 and May 2013, with the last patient completed in August 2013. Recruitment was from IBS clinics at the investigators’ hospital, or from lists of patients who had previously taken part in research studies and had indicated that they would like to be contacted about future relevant research projects. In addition, we had, in conjunction with the local Primary Care Research Network (PCRN), approached general practitioners to ask them to search their databases for eligible participants and send out letters of invitation along with participant information sheets (PISs). Either way, the initial approach was from a member of the patient’s usual care team or from appropriately authorised research nurses. We also advertised in the local newspaper. Initial recruitment into this trial was slow, using the Rome III criteria based on daily diary recordings, whereas previous studies had used reported symptoms based on recall. We felt that the eligibility criteria for IBS-D were too demanding. We therefore modified the eligible criteria for IBS-D following registration with ‘ClinicalTrials.gov’ to reflect the fact that, as others have found, the bowel habit of patients with IBS-D is less abnormal than patients’ reported symptoms suggest.40

The patients were required to meet the modified Rome III criteria for IBS-D, defined as a stool frequency of ≥ 3 per day for > 2 days per week and ≥ 25% of stools to be of types 5–7 [i.e. unlike standard Rome III criteria, which state Bristol Stool Form Scale (BSFS) 6 and 7, to include stool form 5 as well] and < 25% of types 1 and 2 according to the BSFS.41 To exclude other causes of diarrhoea, we required normal colonoscopy and colonic biopsies, normal full blood count, serum calcium and albumin, C-reactive protein and negative serological test for coeliac disease. Lactose intolerance was tested by asking patients to...
consume 568 ml of milk per day and performing a lactose breath hydrogen test if they developed diarrhoeal symptoms within 3 hours. If the stools were watery and frequent then the patient underwent a 7-day retention of selenium-75-labelled homocholic acid taurine test or a trial of cholestyramine to exclude bile acid malabsorption. If any of these tests were positive then the patient was excluded from the study. All patients gave written consent. Another inclusion criterion was age 18–75 years. Exclusion criteria were prior history of major abdominal surgery; liver or kidney impairment; or chronic ingestion of any anti-inflammatory drugs or medications that could affect the gut motility. All childbearing female patients tested negative on the pregnancy test during the randomisation day and had to agree to adequate contraception during the trial. Patients who were on long-term selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs) were included if they were on a stable dose for 3 months and undertook to sustain the dose unaltered throughout the trial. During the screening period of 2 weeks, patients were allowed a maximum of only two doses of 4 mg loperamide (Immodium®, Janssen) per week and discontinued any IBS medication. Once randomised, patients were allowed to take loperamide to control their symptoms, as we hypothesised that mesalazine would take at least 6 weeks to exert its effect on the gut. During the last 2 weeks of the trial when the primary end points were being assessed, patients were not allowed loperamide or any antibiotics. Ethical approval was sought for any adverts or posters displayed in the relevant clinical areas. Patients were seen in the research centres in participating hospitals and enrolled by research nurses or doctors.

Patient visits and contacts are shown in Table 1.

Inclusion criteria

1. Male or female patients, aged 18–75 years, able to give informed consent.
2. Patients should all have had a colonoscopy or sigmoidoscopy within the last 12 months to exclude microscopic or any inflammatory colitis (if not, but they have had a negative colonoscopy within 5 years and symptoms are unchanged, then a sigmoidoscopy and mucosal biopsy of the left colon would be sufficient to exclude microscopic or any inflammatory colitis).
3. Patients with IBS-D, meeting Rome III criteria prior to screening phase.
4. Patients with ≥25% soft stools (score >4, i.e. 5–7) and <25% hard stools (score 1 or 2) during the screening phase, as scored by the daily symptom and stool diary.*
5. Patients with a stool frequency of ≥3 per day for ≥2 days per week during the screening phase.*
6. Satisfactory completion of the daily stool and symptom diary during the screening phase at the discretion of the investigator.
7. Women of childbearing potential willing and able to use at least one highly effective contraceptive method throughout the study. In the context of this study, an effective method is defined as those that result in low failure rate (i.e. <1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, sexual abstinence or vasectomised partner.

*If inclusion criterion 4 and/or 5 is/are not met but the results are considered atypical (as observed from medical history and patient recall) then the patient can be rescreened on one occasion only. There must be sufficient data completed during the screening phase to allow adequate classification.

Definition of diarrhoea-predominant irritable bowel syndrome meeting the Rome III criteria
This was defined as abdominal pain or discomfort at least 2–3 days per month in the last 3 months (criterion fulfilled for the last 3 months with symptom onset at least 6 months prior to screening) associated with two or more of the following:

- improvement with defecation
- onset associated with a change of stool frequency
- onset associated with a change in form (appearance) of stool.
<table>
<thead>
<tr>
<th>Procedure</th>
<th>Visit 1: screening (T = −2)</th>
<th>Visit 2: randomisation (T = 0, from first dose)</th>
<th>Telephone contact (T = 1)</th>
<th>Telephone contact* (T = 3)</th>
<th>Visit 3 (T = 6)</th>
<th>Telephone contact* (T = 9)</th>
<th>Visit 4: final visit (T = 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Check eligibility</td>
<td>•</td>
<td>•</td>
<td>Check on diary completion, AE check, concurrent medication and treatment tolerance</td>
<td>Check on diary completion, AE check, concurrent medication and treatment tolerance</td>
<td>•</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Informed consent</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics and bowel symptoms</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination and history</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daily symptom and stool diary</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sigmoidoscopy with biopsy to exclude microscopic colitis</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomisation</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Questionnaires</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood and stool sample</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flexible sigmoidoscopy and biopsies</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI scans</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMP Dispense</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Return</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adverse reaction recording

AE, adverse event; IMP, investigational medicinal product; T, time (weeks).

a Telephone contact was by telephone or e-mail, or, if convenient, at the hospital.
b Daily symptom and stool diary was completed throughout the participant’s involvement in the trial. This was reviewed at each visit.
c Unless the participant had undergone a colonoscopy within the last 12 months that excluded microscopic or any inflammatory colitis.
d Centers for Disease Control and Prevention health-related quality of life Healthy Days Core Module, European Quality of Life-5 Dimensions, Hospital Anxiety and Depression Scale and Patient Health Questionnaire 15.
e Only participants recruited at the Nottingham site underwent MRI scans and flexible sigmoidoscopy with biopsies.

Note: dots represent the tasklist for each visit.
Exclusion criteria

1. Women who are pregnant or breastfeeding.
2. Prior abdominal surgery that may cause bowel symptoms that are similar to IBS (note appendectomy and cholecystectomy will not be exclusions).
3. Patients unable to stop antimuscarinic drugs, antispasmodic drugs, high-dose TCAs (i.e. > 50 mg/day), opiates/antidiarrhoeal drugs,* non-steroidal anti-inflammatory drugs (occasional over-the-counter use and topical formulations are allowed), long-term antibiotic drugs, other anti-inflammatory drugs or 5-ASA-containing drugs.
4. Patients on SSRIs and low-dose TCAs (i.e. ≤ 50 mg/day) for at least 3 months, previously unwilling to remain on a stable dose for the duration of the trial.
5. Patients with other gastrointestinal diseases, including colitis and Crohn’s disease.
6. Patients with the following conditions: renal impairment, severe hepatic impairment or salicylate hypersensitivity.
7. Patients currently participating in another trial or who have been involved in a trial within the previous 3 months.
8. Patients who in the opinion of the investigator are considered unsuitable owing to an inability to comply with instructions.
9. Patients with serious concomitant diseases, for example cardiovascular, respiratory, neurological, etc.

(A full list of excluded or dose-controlled medications can be found in Appendix 1.)

*Loperamide is allowed as rescue medication throughout the trial; however, if > 2 doses per week are taken during the screening phase then they are not eligible, although they can be rescreened on one occasion only.

Expected duration of participant participation
Study participants participated in the study for 14 weeks.

Removal of participants from therapy or assessments
The following subject withdrawal criteria applied:

1. Non-compliance – if < 75% of the investigational medicinal product (IMP) doses are taken between visits, at the investigator’s discretion. (Dose as advised by the study doctor, taking into account that not all participants will be advised to take the full study dose owing to intolerance.)
2. If the participant has remained on the initial lower dose of 2 g once a day for 3 weeks and the medication is still not tolerated, at the investigator’s discretion.
3. Adverse reaction (serious and non-serious) with clear contraindications.
4. Participant withdraws consent.
5. Safety reasons, for example pregnancy.*
6. Lost to follow-up.
7. Participant develops an excluded/contraindicated condition.
8. Investigator discretion (e.g. protocol violations).
9. Unblinding, at the discretion of the principal investigator in conjunction with the chief investigator.

*In the event of a pregnancy occurring in a trial participant or the partner of a trial participant, monitoring will occur during the pregnancy and after delivery to ascertain any trial-related adverse events (AEs) in the mother or the offspring. When pregnancy occurs in the partner of a trial participant, consent will be obtained for this observation from both the partner and her medical practitioner.

Participants withdrawn from the study were replaced. The participants were told that withdrawal would not affect their future care. Participants were also made aware (via the information sheet and consent form) that, should they withdraw, the data collected up to their withdrawal could not be erased and may still be used in the final analysis.
Chapter 4  Main outcome measures

Clinical outcomes

Primary outcome

1. Daily mean stool frequency during weeks 11–12 of the treatment period.

Secondary outcomes (all assessed during weeks 11–12 of the treatment period)

1. Average daily severity of abdominal pain on a 0–10 scale.
2. Days with urgency during weeks 11–12 post randomisation.
3. Mean stool consistency using BSFS.
4. Global satisfaction with control of IBS symptoms, as assessed from the answer to the question ‘Have you had satisfactory relief of your IBS symptoms this week? Yes/no’.

Ancillary secondary end points

1. European Quality of Life-5 Dimensions (EQ-5D).
2. Centers for Disease Control and Prevention health-related quality of life Healthy Days Core Module (CDC HRQOL4).
3. Hospital Anxiety and Depression Scale (HADS).

Safety end points

1. AEs related to the trial treatment.
2. Withdrawal from the trial treatment as a result of AEs.

Mechanistic outcomes

Primary outcome

1. Mast cell numbers (mean percentage area stained) at week 12.

Secondary outcomes

1. Mast cell tryptase release during 6-hour biopsy incubation.
2. IL-1β, TNF-α, histamine and 5-HT secretion during same incubation.
3. Small bowel tone assessed by volume of fasting small bowel water.
4. Faecal tryptases and calprotectin.
5. Difference in primary outcome measure between those with different TNFSF15 polymorphism will be assessed using analysis of variance (ANOVA).
Chapter 5  Sample size

Our previous study on patients with IBS-D gives a mean stool frequency of 3.1 [standard deviation (SD) 2.0]. Tuteja et al.\textsuperscript{24} reported mesalazine decreasing stool frequency by 1.4 bowel movements per day. Our study had 80% power to detect such an effect at the 1% two-sided alpha level. We aimed to randomise at least 125 patients to allow for 20% dropout rate but, owing to recruitment ongoing at multiple sites and patient requests, we actually recruited 136.

Much smaller numbers are needed to assess the effect of mesalazine on mast cell numbers and tryptase release. Corinaldesi et al.\textsuperscript{23} reported a 36% decrease in mast cell numbers from a mean of 9.2% over lamina propria area, that is 2.96% over lamina propria area (SD 2.5% over lamina propria area), which, assuming average change on placebo is 0, requires just 16 patients to show a significant difference with a power of 90% at the 5% alpha level.
Chapter 6 Data analysis

Analysis and presentation of data was in accordance with Consolidated Standards of Reporting Trials (CONSORT) guidance. The primary data set included stool diary filled for at least 10 days out of 14. Balance between the trial arms at baseline was examined using appropriate descriptive statistics. For continuous variables, data were summarised in terms of the mean, SD, median, lower and upper quartiles, minimum, maximum and number of observations. Categorical variables were summarised in terms of frequency counts and percentages.

The general approach for between-group comparisons was intention to treat (ITT). Appropriate regression modelling was used to evaluate the primary and secondary outcomes, and safety data, with due emphasis placed on clinical importance of 95% confidence intervals (CIs) for between-group estimates.

No formal adjustment for multiple significance testing was applied. We also performed a sensitivity analysis using multiple imputation of missing data for the primary outcome.

Full details were given in a separate Statistical Analysis Plan approved before data lock.

The safety monitoring functions of the trial was undertaken by the Data Monitoring and Ethics Committee (DMEC).

Assessment of efficacy

We used descriptive statistics to compare the randomised groups at baseline. The primary outcome was assessed using ITT without imputation. We used a generalised linear mixed model to compare the mesalazine group and placebo group for the primary outcome, with adjustment for the baseline value of the outcome, and study centre as a random effect. Additionally, we adjusted for any variables showing imbalance at baseline in secondary models. We compared the characteristics of participants who did and did not adhere with the study medication before estimating the treatment effect if the medication was actually taken using Complier Average Causal Effect (CACE) analysis. We investigated the effect of missing primary outcome data using multiple imputation. The secondary outcomes were assessed using similar models as for primary outcome, or logistic or Poisson regression, as appropriate, dependent on outcome type.

We undertook subgroup analyses by including appropriate interaction terms in the linear mixed model for primary outcome according to baseline daily mean stool frequency, baseline mean abdominal pain score and baseline mean HADS anxiety score.

Secondary outcomes were treated similarly, after transformation if appropriate, whereas binary and count outcomes were handled by multiple logistic or Poisson regression, as appropriate. Given the large number of potential comparisons, p-values for mechanistic variables will not be presented. All analyses were performed using Stata version 13 (StataCorp LP, College Station, TX, USA) adopting the ITT principle without imputation for missing data (with a sensitivity analysis using multiple imputation for the primary outcome).

We planned to conduct a number of prespecified subgroup analyses.
For each of the three outcomes listed below, we investigated whether or not there were any differences in between-group effects according to the following baseline variables: anxiety, stool frequency, abdominal pain and mast cell activation:*

1. stool frequency during weeks 11–12
2. number of days with any stool consistency scoring 6 or 7 during weeks 11–12
3. mean score of worst pain for each day, averaged over weeks 11 and 12.

*Mast cell activation will be defined as elevation of any of the inflammatory mediator components, such as mast cell tryptase, IL-1β, TNF-α, histamine and 5-HT in biopsy supernatant.

These subgroup analyses were conducted by including appropriate interaction terms in the regression models and, as the study has not been powered to detect any such subgroup effects, were considered as exploratory and would require confirmation in future research.

The primary mechanism hypothesis to be investigated was that treatment with mesalazine reduces inflammation, which, in turn, reduces clinical symptoms. The aim of this type of analysis is to estimate how much of any observed treatment effect can be attributed to a variable that is thought to be an intermediate on the causal pathway, or mediator.

After summarising inflammatory markers at baseline and 11–12 weeks’ follow-up by trial arm using appropriate descriptive statistics, we will examine change in these markers (stool calprotectin, mast cell tryptase, mast cell percentage area stained) and change in stool frequency using a scatter plot.

**Definition of populations analysed**

*Safety set* All randomised participants who receive at least one dose of the study drug. All AEs in this set are reported.

*ITT set* All randomised participants for whom at least one post-baseline assessment of the primary end point is available.

**Stool samples and sigmoid colon biopsies**

These were collected at week 0 and the end of trial (EOT) from patients recruited in Nottingham. Stools collected were analysed for calprotectin. A commercially available calprotectin enzyme-linked immunosorbent assay (ELISA) kit (Buhlmann, Schönenbuch, Switzerland) was used for extraction and quantification of stool calprotectin. Samples were analysed for faecal tryptase based on a method published recently by our group.42 Faecal protease activity is expressed in trypsin units per mg of protein.
Sigmoid biopsies were collected for immunohistochemistry for mast cell tryptase, CD3, CD68 (a marker of macrophage) and 5-HT, and tissues were processed and stained in the histopathology laboratory in Nottingham University Hospitals NHS Trust, UK. A further set of biopsies was maintained in culture and supernatants collected were assayed for (1) mast cell tryptase, chymase, carboxypeptidase A3 (CPA3) and histamine, and (2) IL-1β and TNF-α levels. The biopsy tissues were incubated immediately in Hanks’ medium for 30 minutes before storing at –80 °C until assays for (1) mast cell mediators were performed by the Immunopharmacology Group at the University of Southampton; and (2) IL-1β and TNF-α levels were performed by RI, Research Fellow in Centre of Biomolecular Science, University of Nottingham. Levels of IL-1β and TNF-α was analysed by using a commercial kit V-PLEX immunoassay (Meso Scale Discovery, Rockville, MD, USA).

**Histological methods (see Appendix 2)**

Mast cell numbers were assessed as the mean of area percentage stained per region of interest (m²).

**Faecal tryptase**

Stool samples were collected at baseline (randomisation day) and at the EOT (end of week 12).
Chapter 7 Results

Of 221 patients initially screened, 185 were eligible and 136 were enrolled and randomised into the study (Figure 1). Follow-up was completed in August 2013. The most frequent reason for exclusion was disinclination to participate. The commonest reason for not meeting inclusion criteria was that the patients’ diaries during the 2 weeks’ run-in period indicated that they did not have loose stools \( \geq 25\% \) of the time or stool frequency of \( \geq 3 \) per day for \( \geq 2 \) days per week.

Demographics

A total of eight sites participated in this study. Table 2 and Appendix 2 (see Table 16) show a summary of recruitment by site and by treatment arm.

Characteristics of enrolled patients in both groups were similar at baseline (Table 3).

Primary and secondary outcome data were collected for 115 (85\%) and 116 (85\%) participants, respectively, at 11–12 weeks of follow-up.

---

**FIGURE 1** Patient flow chart (CONSORT diagram).
Clinical primary outcome

The primary ITT comparison showed no evidence of any clinically significant difference between mesalazine and placebo for the primary outcome (Table 4). Additional adjustments for variables (age, abdominal pain score, number of days with urgency and PHQ-15 score) displaying imbalance at baseline did not materially change the results (Table 5a) and nor did multiple imputation analysis or CACE analysis (Table 5b–c).

Subgroup analyses (Table 6a) of the primary outcome by baseline daily mean stool frequency suggest that mesalazine may be more effective among patients with greater baseline stool frequency and is associated with larger treatment effect, but this could be a chance finding and would require confirmation in further studies. There was no evidence that treatment effect differed according to baseline pain or HADS (Table 6b and c). Our sensitivity analysis, using multiple imputation of missing data for the primary outcome, showed no effect on primary outcome (see Table 6b).
### TABLE 4  Clinical primary outcome of daily mean stool frequency at weeks 11–12

<table>
<thead>
<tr>
<th>Group/comparison</th>
<th>Daily mean stool frequency at 11–12 weeks, mean (SD)</th>
<th>Between-group difference at 11–12 weeks (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>2.7 (1.9) ( (n = 58) )</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine</td>
<td>2.8 (1.2) ( (n = 57) )</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine vs. placebo</td>
<td>–</td>
<td>0.10 (-0.33) to 0.53 )</td>
<td>0.658</td>
</tr>
</tbody>
</table>

### TABLE 5a  Primary analysis of average stool frequency with further adjustment of baseline covariates

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Adjusted* difference in mean frequency</th>
<th>p-value</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesalazine vs. placebo</td>
<td>0.13</td>
<td>0.562</td>
<td>(-0.31) to (0.57)</td>
</tr>
</tbody>
</table>

* Adjusted by age, study centre and baseline daily mean stool frequency.

### TABLE 5b  Primary analysis of average stool frequency with multiple imputation

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Adjusted* difference in mean frequency</th>
<th>p-value</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesalazine vs. placebo</td>
<td>0.06</td>
<td>0.172</td>
<td>(-0.18) to (0.99)</td>
</tr>
</tbody>
</table>

* Adjusted by baseline daily mean stool frequency and study centre.

### TABLE 5c  Primary analysis of average stool frequency (CACE)

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Adjusted* difference in mean frequency</th>
<th>p-value</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesalazine vs. placebo</td>
<td>0.16</td>
<td>0.669</td>
<td>(-0.58) to (0.91)</td>
</tr>
</tbody>
</table>

* Adjusted by baseline daily mean stool frequency and study centre.

### TABLE 6a  Primary outcome subgroup analysis by baseline stool frequency

<table>
<thead>
<tr>
<th>Baseline frequency</th>
<th>Placebo ((n = 58))</th>
<th>Mesalazine ((n = 57))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily mean stool frequency at 11–12 weeks by baseline frequency, mean (SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\leq 2.4)</td>
<td>1.6 (0.5)</td>
<td>1.7 (0.4)</td>
</tr>
<tr>
<td>(&gt; 2.4 \text{ and } \leq 3.4)</td>
<td>2.2 (1.1)</td>
<td>2.2 (0.5)</td>
</tr>
<tr>
<td>(&gt; 3.4 \text{ and } \leq 4.6)</td>
<td>2.7 (0.9)</td>
<td>3.1 (1.3)</td>
</tr>
<tr>
<td>(&gt; 4.6)</td>
<td>4.7 (2.9)</td>
<td>4.1 (1.1)</td>
</tr>
</tbody>
</table>

Estimates* for interaction in primary analysis model with 95% CI and p-value

Primary outcome by baseline stool frequency \(-0.26 (-0.51\) to \(-0.01\); \(p = 0.043\)

* Adjusted by baseline daily mean stool frequency and study centre.
RESULTS

Clinical secondary outcomes

No differences were apparent for any of the secondary outcomes, with the exception of number of days with urgency (Table 7), which were increased by about 20% on mesalazine treatment compared with placebo.

Compliance

Compliance was defined a priori as taking ≥ 75% of the medication throughout the 12 weeks. Each patient was given two boxes of medication during the 12-week study, each box containing 100 sachets. The amount of medication taken was calculated by 200 minus the number of medication sachets returned at EOT. Compliance with medication (Table 8) and baseline characteristics of compliers (defined as taking ≥ 75% of the medication throughout the 12 weeks) were similar in both groups. Analysis of the primary outcome using the CACE approach showed no difference between the two treatment arms (mean difference 0.2, 95% CI –0.6 to 0.9).

| Table 6b Primary outcome subgroup analysis by baseline abdominal pain score |
| Baseline pain score | Placebo (n = 58) | Mesalazine (n = 57) |
| Daily mean stool frequency at 11–12 weeks by baseline abdominal pain score, mean (SD) |
| ≤ 2.2 | 2.9 (2.8) | 2.7 (0.9) |
| > 2.2 and ≤ 4.1 | 2.6 (1.4) | 2.4 (0.7) |
| > 4.1 and ≤ 5.3 | 2.4 (1.4) | 3.0 (1.6) |
| > 5.3 | 3.2 (1.7) | 2.9 (1.3) |

Estimates* for interaction in primary analysis model with 95% CI and p-value

Primary outcome by baseline pain score: –0.03 (–0.10 to 0.04); p = 0.361

* Adjusted by baseline daily mean stool frequency and study centre.

| Table 6c Primary outcome subgroup analysis by baseline HADS score |
| Baseline HADS score | Placebo (n = 58) | Mesalazine (n = 57) |
| Daily mean stool frequency at 11–12 weeks by baseline HADS score, mean (SD) |
| ≤ 5.0 | 3.1 (3.2) | 3.0 (1.4) |
| > 5.0 and ≤ 9.0 | 2.3 (1.3) | 2.8 (1.2) |
| > 9.0 and ≤ 11.5 | 3.0 (1.5) | 2.9 (1.3) |
| > 11.5 | 2.0 (0.9) | 2.6 (1.3) |

Estimates* for interaction in primary analysis model with 95% CI and p-value

Primary outcome by baseline HADS score: –0.01 (–0.04 to 0.03); p = 0.792

* Adjusted by baseline daily mean stool frequency and study centre.
### TABLE 7  Secondary outcome results

<table>
<thead>
<tr>
<th>Treatment outcome with mesalazine or placebo</th>
<th>Baseline</th>
<th>11–12 weeks</th>
<th>Between-group comparison at 11–12 weeks (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily mean abdominal pain score, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>3.6 (2.0)</td>
<td>2.2 (2.1) (n = 59)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine</td>
<td>4.1 (2.2)</td>
<td>2.8 (2.1) (n = 57)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine vs. placebo</td>
<td>–</td>
<td>–</td>
<td>0.07 (–0.54 to 0.68)</td>
<td>0.828</td>
</tr>
<tr>
<td>Number of days with urgency, median (IQR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>12 (9–14)</td>
<td>8 (1–13) (n = 59)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine</td>
<td>13 (10–14)</td>
<td>11 (5–14) (n = 57)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine vs. placebo</td>
<td>–</td>
<td>–</td>
<td>1.22 (1.07 to 1.39)</td>
<td>0.003</td>
</tr>
<tr>
<td>Weekly mean stool consistency, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>5.6 (1.0)</td>
<td>4.7 (1.1) (n = 59)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine</td>
<td>5.4 (0.7)</td>
<td>4.7 (1.0) (n = 57)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine vs. placebo</td>
<td>–</td>
<td>–</td>
<td>0.13 (–0.21 to 0.48)</td>
<td>0.452</td>
</tr>
<tr>
<td>Number of days with consistency score 6 or 7, median (IQR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>11 (8–13)</td>
<td>6 (2–9) (n = 59)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine</td>
<td>11 (8–13)</td>
<td>7 (2–11) (n = 57)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine vs. placebo</td>
<td>–</td>
<td>–</td>
<td>1.09 (0.95 to 1.27)</td>
<td>0.210</td>
</tr>
<tr>
<td>Mean HADS score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>8.6 (4.3)</td>
<td>6.9 (3.6) (n = 59)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine</td>
<td>9.0 (4.5)</td>
<td>7.5 (5.0) (n = 57)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine vs. placebo</td>
<td>–</td>
<td>–</td>
<td>0.67 (–0.38 to 1.72)</td>
<td>0.210</td>
</tr>
<tr>
<td>Mean PHQ-15 score, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>13.1 (5.6)</td>
<td>9.4 (5.0) (n = 59)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine</td>
<td>12.6 (5.2)</td>
<td>10.0 (5.2) (n = 57)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine vs. placebo</td>
<td>–</td>
<td>–</td>
<td>0.63 (–0.93 to 2.20)</td>
<td>0.428</td>
</tr>
<tr>
<td>Number of people with satisfactory relief of IBS symptoms, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>0</td>
<td>24 (40.7) (n = 59)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine</td>
<td>0</td>
<td>25 (43.9) (n = 57)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mesalazine vs. placebo</td>
<td>–</td>
<td>–</td>
<td>1.13 (0.51 to 2.47)</td>
<td>0.762</td>
</tr>
</tbody>
</table>
## RESULTS

### TABLE 7 Secondary outcome results (continued)

<table>
<thead>
<tr>
<th>EQ-5D: five division components that have no problems, n (%)</th>
<th>Baseline Placebo Mean (SD)</th>
<th>Placebo Mean (SD)</th>
<th>Mesalazine Mean (SD)</th>
<th>Between-group comparison (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mobility</td>
<td>46 (67.6)</td>
<td>53 (77.9)</td>
<td>47 (79.3)</td>
<td>44 (77.2)</td>
<td></td>
</tr>
<tr>
<td>Self-care</td>
<td>66 (97.1)</td>
<td>63 (92.6)</td>
<td>57 (96.6)</td>
<td>52 (91.2)</td>
<td></td>
</tr>
<tr>
<td>Usual activity</td>
<td>39 (57.4)</td>
<td>44 (64.7)</td>
<td>44 (74.6)</td>
<td>45 (78.9)</td>
<td></td>
</tr>
<tr>
<td>Pain/discomfort</td>
<td>7 (10.3)</td>
<td>8 (11.8)</td>
<td>15 (25.4)</td>
<td>15 (26.3)</td>
<td></td>
</tr>
<tr>
<td>Anxiety/depression</td>
<td>39 (57.4)</td>
<td>39 (57.4)</td>
<td>37 (62.7)</td>
<td>35 (61.4)</td>
<td></td>
</tr>
</tbody>
</table>

EQ VAS, EuroQol visual analogue scale; IQR, interquartile range.

a Estimate depends on type of outcome variable and is adjusted by baseline value of the outcomes if appropriate.

b Difference in means.

c Incidence rate ratio.

d Odds ratio.

### TABLE 8 Summary of compliance with trial medication (participants who completed 12 weeks of treatment)

<table>
<thead>
<tr>
<th>Compliance with medication</th>
<th>Placebo (n = 59)</th>
<th>Mesalazine (n = 57)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compliance,* mean (SD) %</td>
<td>72 (17)</td>
<td>71 (19)</td>
</tr>
<tr>
<td>Complier,b n (%)</td>
<td>35 (59)</td>
<td>33 (58)</td>
</tr>
</tbody>
</table>

a Calculated as 100 minus the proportion of trial medication returned.

b Complier is defined as compliance ≥75%.
Adverse events

The most frequently occurring side effect was exacerbation of IBS symptoms, which could be worsening abdominal pain or diarrhoea. Two patients (3%) from the mesalazine group and three (5%) from the placebo group complained of this and were withdrawn from the study. Other less frequent side effects are listed in Appendix 2 (see Table 15). One patient was pregnant in the middle of the trial period, although she had a negative result in a pregnancy test at the start of the trial. She was withdrawn from study with no adverse consequence to her or her newborn.43 One patient from the mesalazine group was found to have breast cancer and she was withdrawn from the study, as her IBS symptoms and stool diary would have been very difficult to interpret. All participants who developed these AEs were withdrawn from the study and their symptoms settled on follow-up – see Appendix 2, Table 15.

Mechanistic primary outcome

Mast cells

The mast cell percentage area stained was not elevated in patients with IBS-D compared with our normal range that was established previously in our laboratory. The baseline mast cell percentage area stained for patients with IBS-D was median 2.25% [interquartile range (IQR) 1.86–2.73%], compared with median 2.42% (IQR 2.09–3.39%) in the healthy control subjects (Figure 2). There was no reduction in mast cell percentage area stained following treatment with mesalazine (Figure 3 and Table 9).

![Figure 2](image-url) Mast cell count assessed from percentage area stained comparing healthy control subjects and patients with IBS-D (median, IQR).
FIGURE 3  Effect of mesalazine vs. placebo on mast cell percentage area stained in patients with IBS-D (median, IQR).

TABLE 9  Effect of mesalazine vs. placebo on mast cell percentage area stained/m² in patients with IBS-D [median (IQR)]

<table>
<thead>
<tr>
<th></th>
<th>Mesalazine</th>
<th></th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>After treatment</td>
<td>Baseline</td>
</tr>
<tr>
<td>Mesalazine</td>
<td>2.11 (1.06–2.11)</td>
<td>2.29 (1.86–2.75)</td>
<td>2.33 (1.88–2.74)</td>
</tr>
</tbody>
</table>
Mechanistic secondary outcome

Mast cell tryptase and other mediator release during biopsy incubation

Baseline supernatant levels were compared between patients with IBS-D and our normal range in healthy volunteers. There was no significant increase in the baseline mediator levels except CPA3 (Figure 4 and Table 10).

Following treatment with either mesalazine or placebo in the patients with IBS-D, there was no change in the supernatant levels of the mediators (Table 11 and Figures 5–9).

![FIGURE 4 Baseline CPA3 levels in patients with IBS-D. Shaded area indicates normal range in HVs (median, IQR).](image)

<table>
<thead>
<tr>
<th>Mediator</th>
<th>HVs, ( n = 21 )</th>
<th>IBS-D patients, ( n = 45 )</th>
<th>( p )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tryptase</td>
<td>6.7 (3.8–11.4)</td>
<td>4.3 (1.8–8.9)</td>
<td>0.07</td>
</tr>
<tr>
<td>Chymase</td>
<td>0</td>
<td>0 (0–0.9)</td>
<td>0.14</td>
</tr>
<tr>
<td>CPA3</td>
<td>0.34 (0.28–0.52)</td>
<td>0 (0–0.9)</td>
<td>0.0496</td>
</tr>
<tr>
<td>Histamine</td>
<td>1.6 (0.7–3.8)</td>
<td>0.7 (0–1.3)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

**TABLE 10** Baseline supernatant levels (ng/ml) between HVs and patients with IBS-D [median (IQR)]

<table>
<thead>
<tr>
<th>Supernatant mediators</th>
<th>Mesalazine baseline (( n = 21 ))</th>
<th>Placebo baseline (( n = 23 ))</th>
<th>Mesalazine after treatment</th>
<th>Placebo after treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tryptase</td>
<td>4.3 (1.5–8.6)</td>
<td>4.6 (2.5–9.1)</td>
<td>4.9 (1.8–8.2)</td>
<td>5.8 (2.1–10.3)</td>
</tr>
<tr>
<td>Chymase</td>
<td>0 (0–0.3)</td>
<td>0 (0–0.8)</td>
<td>0 (0–1.7)</td>
<td>0 (0–0.4)</td>
</tr>
<tr>
<td>CPA3</td>
<td>0 (0–0.3)</td>
<td>0 (0–1.0)</td>
<td>0 (0–0.8)</td>
<td>0 (0–0.5)</td>
</tr>
<tr>
<td>Histamine</td>
<td>0.9 (0.3–1.4)</td>
<td>0.7 (0–1.4)</td>
<td>0.8 (0–1.2)</td>
<td>0.7 (0.2–1.0)</td>
</tr>
<tr>
<td>5-HT</td>
<td>9.4 (6.1–15.1)</td>
<td>6.3 (2.7–13.7)</td>
<td>10.7 (5.4–14.0)</td>
<td>9.3 (3.4–14.7)</td>
</tr>
</tbody>
</table>

**TABLE 11** Supernatant mediator levels (ng/ml) following treatment with mesalazine or placebo [median (IQR)]
RESULTS

FIGURE 5 Tryptase levels before and after treatment with mesalazine or placebo (median, IQR).

FIGURE 6 Chymase levels before and after treatment with mesalazine or placebo (median, IQR).
FIGURE 7 Carboxypeptidase A3 levels before and after treatment with mesalazine or placebo (median, IQR).

FIGURE 8 Histamine levels before and after treatment with mesalazine or placebo (median, IQR).
**RESULTS**

**Interleukin-1 beta, tumour necrosis factor alpha**
Levels of IL-1β and TNF-α in supernatant were below the level of detection.

**Small bowel tone assessed by volume of fasting small bowel water**
Fasting small bowel water showed wide variability, ranging from 5 to 220 ml. This did not alter significantly after treatment with either mesalazine or placebo (Table 12, Figures 10 and 11).

**Faecal tryptases**
Totals of 27 and 30 pairs of stool samples were collected in the mesalazine and placebo groups, respectively. The baseline faecal trypase level was in the range of between 6.8 and 577.8 trypsin units/mg of protein, which was highly variable. There was a significant increase in faecal trypase after treatment with mesalazine (Table 13 and Figure 12). There was no correlation between baseline faecal trypase level and baseline supernatant trypase level: Spearman’s $r = 0.13$, $p = 0.41$. There was no significant correlation between baseline faecal trypase level and anxiety, depression or bowel symptoms.

**Difference in primary outcome measure between those with different TNFSF15 polymorphism**
Genotyping has yet to be done but, given the predicted small numbers with the risk allele and the lack of evidence of immune activation, a significant gene effect is unlikely to be detected.

**TABLE 12** Fasting small bowel water content (ml) following treatment with either mesalazine or placebo

<table>
<thead>
<tr>
<th>Fasting small bowel water content (ml), median (IQR)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesalazine baseline ($n = 17$)</td>
<td>Placebo baseline ($n = 20$)</td>
</tr>
<tr>
<td>58 (27–122)</td>
<td>58 (28–106)</td>
</tr>
</tbody>
</table>

**FIGURE 9** Serotonin levels before and after treatment with mesalazine or placebo (median, IQR).
**FIGURE 10** Fasting small bowel water before and after treatment with mesalazine or placebo (median, IQR).

**FIGURE 11** Changes in fasting small bowel water before and after treatment with either mesalazine or placebo.

**TABLE 13** Faecal tryptase levels (trypsin units/mg protein) following treatment with mesalazine or placebo

<table>
<thead>
<tr>
<th></th>
<th>Baseline, median (IQR)</th>
<th>After treatment, median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesalazine (n = 30)</td>
<td>61.2 (37.6–101.4)</td>
<td>82.7 (40.5–194.8)</td>
</tr>
<tr>
<td>Placebo (n = 27)</td>
<td>66.5 (44.8–126.5)</td>
<td>70.9 (36.0–191)</td>
</tr>
</tbody>
</table>

© Queen’s Printer and Controller of HMSO 2015. This work was produced by Lam et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
RESULTS

**Post hoc analysis**

**Mast cell percentage area stained**

There was no correlation between mast cell percentage area stained with clinical features, such as abdominal pain severity, urgency, bloating, daily mean stool frequency or stool consistency.

We found no significant correlation of mast cell percentage area stained with objective measures of tryptase, chymase, CPA3 and histamine in biopsy supernatants.

**Other immune cells, for example CD3⁺ T lymphocyte, CD68- and serotonin-containing enterochromaffin cells**

There was no effect on either treatment with mesalazine or placebo on CD68-staining macrophages or on 5-HT-containing enterochromaffin cells. There was a paradoxical increase in CD3 count following treatment with mesalazine for reasons which are unclear (Figure 13).

**Stool calprotectin**

Samples were obtained from 53 patients (30 placebo group, 23 mesalazine group). Baseline stool calprotectin levels varied widely, ranging from undetectable to as high as 420 µg/g. There was a negative correlation between calprotectin levels and baseline total HADS score but this did not reach significance ($r = 0.25$, $p = 0.07$) (Figure 14).

When patients were divided into two groups based on stool calprotectin levels of $\leq 100$ µg/g (group B) and $\geq 101$ µg/g (group A), the group with higher calprotectin levels ($\geq 101$ µg/g, group A) at baseline showed a significantly lower total HADS score than the normal calprotectin level group (group B) (Figure 15). Otherwise, comparing these two groups, there were no differences with their baseline clinical characteristics such as abdominal pain severity, average daily stool frequency and stool consistency.

![FIGURE 12 Change in faecal tryptase following treatment with mesalazine compared with placebo (median, IQR).](image-url)
**FIGURE 13** CD3+ T lymphocyte count before and after treatment with mesalazine or placebo (median, IQR).

**FIGURE 14** Correlation between baseline calprotectin levels (µg/g) and baseline total HADS score.
Postinfectious irritable bowel syndrome

Thirteen participants met the previously published criteria for PI-IBS. They had to meet Rome III criteria for IBS following an episode of infectious gastroenteritis characterised by ≥ 2 of the following symptoms: fever, vomiting, diarrhoea and positive stool culture. Eight participants were randomised into the mesalazine group and five were allocated to the placebo group. There was significant improvement in clinical symptoms—such as abdominal pain, urgency and stool consistency—following treatment with mesalazine but not with placebo (Figures 16–18).

**FIGURE 15** Baseline stool calprotectin levels when divided into two groups (median, IQR).

**FIGURE 16** Abdominal pain severity before and after treatment with mesalazine or placebo.
FIGURE 17 Urgency symptoms before and after treatment with mesalazine or placebo.

FIGURE 18 Stool consistency before and after treatment with mesalazine or placebo.
Chapter 8 Discussion

Over the past decade, there have been several promising studies using 5-ASA for treatment of both IBS-D and PI-IBS, but sample sizes were small and their significance was uncertain. These studies were motivated by recent findings of ‘immune activation’ in the gut mucosa of patients with IBS, dominated by mast cells and T lymphocytes rather than the polymorphonuclear leucocytes that are characteristic of colitis. These studies were supported by several studies suggesting impaired mucosal barrier in IBS, which, by allowing access of luminal bacterial products to the mucosal immunocytes, might cause this activation. These data suggested that mesalazine, being an anti-inflammatory agent, might benefit this condition. Our study is one of the largest trials so far looking at the treatment of patients with IBS-D with mesalazine following best practice to ensure that both investigators and patients were blinded to the study and that data analysis was carried out by independent statisticians. We analysed the effect of mesalazine only after 12-week treatment, as we felt that mesalazine was a disease-modifying treatment rather than a symptomatic treatment, and early reports suggested that benefit was most obvious after 2–3 months. Our study showed that mesalazine did not improve bowel frequency after 12 weeks’ treatment when compared with placebo in unselected patients. As with other studies of IBS, we found a strong placebo effect on bowel symptoms and also on the total HADS and somatic scores, suggesting that patients felt better, in general, after taking part in the trial.

Despite lack of benefit in unselected patients, we had preplanned subanalysis of the primary outcome of stool frequency in patients who were divided according to severity. This suggested that a group of patients who had the greatest bowel frequency did show a small benefit from mesalazine (mean difference –0.26, p = 0.04). Our clinical findings seem consistent with another recent report. There was no significant improvement, however, in other IBS symptoms, such as abdominal pain, bloating and stool consistency. There is strong evidence from our study that mesalazine treatment increases the number of days with urgency by about 20%. There have been previous case studies reporting treatment with mesalazine worsening diarrhoea in colitis. This may represent an allergic response to the drug, as we did find an increase in T lymphocytes.

Raised mast cells numbers in the gut mucosa have been implicated in all subtypes of IBS, but mainly in IBS-D. Mast cells contain many mediators, including histamine, 5-HT and proteases such as tryptase. Recently, there has been focus of interest on tryptase content, as it has been shown to activate PAR-2, which is found on afferent nerves and can lead to increased sensitivity of bowel distension. In our study, the mast cell percentage area stained in patients with IBS-D was not elevated, compared with that in our previously studied healthy subjects. Despite our large numbers we were able neither to confirm the gender difference in mast cell count of patients with IBS-D, as previously described by others, nor find any gender effect on other immune cells such as CD3-, CD68- and 5-HT-containing enterochromaffin cells.

Similarly, the supernatant levels of tryptase in patients with IBS-D were not significantly elevated, compared with healthy control subjects. Median (IQR) tryptase levels for IBS-D compared with healthy control subjects were 4.3 (1.8–8.9) ng/ml and 6.7 (3.8–11.4) ng/ml; p = 0.07. We were not, therefore, able to confirm either increased mast cell numbers or increased mast cell tryptase release from biopsies, as some, nor all, investigators have found. Our study provides no support for the previous suggestion that mesalazine can reduce mast cell numbers.

Surprisingly, supernatant histamine levels in our study were lower in patients with IBS-D than in healthy control subjects [mean 0.7 (SD 0.6) and mean 1.1 (SD 0.8) ng/ml, respectively; p = 0.02]. Supernatant levels of tryptase and histamine were not altered following treatment with mesalazine. Disappointingly, we found no apparent association correlation between mast cell percentage area stained and supernatant levels of release of the mast cell mediators examined, whether those released by all mast cells (tryptase, histamine) or those restricted to a subpopulation (chymase, CPA3). This suggests that the overall degree of mediator release from colonic mast cells is independent of mast cell numbers, suggesting that factors other than mere numbers determine mediator release.
Stool collected in Nottingham was used to obtain calprotectin level at baseline and EOT. Although a small proportion of patients had raised calprotectin levels (≥ 100 µg/g), we had excluded organic diseases – such as inflammatory bowel disease – in gastroenterology clinics using standard tests prior to the patients entering the study. Others have also reported that up to one-quarter of patients with IBS have marginally elevated calprotectin levels, although the origin of this is unclear. Interestingly, the subgroup of patients (group A) who had raised calprotectin levels (≥ 101 µg/g) have significantly less psychological distress than the group with stool calprotectin level of ≤ 100 µg/g (group B). We speculate that subgroup A symptoms are secondary to local gut inflammation, whereas subgroup B symptoms are driven primarily by distress, which causes gut symptoms secondarily. Unfortunately, numbers were too small to answer the question of whether or not subgroup A responded better to mesalazine. Stool calprotectin could, therefore, be used as a screening tool to allow more detailed studies of the mucosa in IBS-D in the future.

One uncontrolled study has suggested that mesalazine might be effective in treating patients with PI-IBS, but the only randomised controlled trial of mesalazine in this condition was negative, although possibly underpowered. In our post hoc analysis, a small subgroup fulfilling criteria for PI-IBS appeared to benefit from mesalazine, but our study was also underpowered. Confirming this would require a larger and more adequately powered study.

Although mesalazine has been available to use for many decades with a good safety profile, our adequately powered study has shown that it does not help the majority of patients with IBS-D. The fact that certain subgroups might benefit emphasises that there is still a need for better phenotyping of this heterogeneous group of patients when evaluating new treatments.

**Limitations**

Despite strict entry criteria, our population was still heterogeneous. In retrospect, it would have been better if we had stratified by postinfectious onset. We did consider this but felt that this would make it very difficult to recruit to the trial. We could overcome this in future studies by having a greatly many more recruitment sites and around five times as many participants, given that PI-IBS accounts for only around 20% of all cases of IBS-D, but this would require more resources than those that we had available to us. It is worth noting that there is an appreciable loss to follow-up (15.5%) but this is not out of line with other similar studies. Dropouts are mostly likely due to failure of treatment and so are unlikely to account for our negative result.

**Research recommendations**

1. Our data suggest that it is unlikely that future trials of mesalazine in unselected IBS would be fruitful.
2. If there is a subgroup that may benefit it is likely to be those with postinfective IBS, particularly those postinfective patients with more severe diarrhoea.
3. The link between mast cells and clinical symptoms is weak and, again, future work on the role of mast cells needs to better characterise the patients, as the majority of unselected patients with IBS do not have elevated mast cell numbers. It may be that, as others have reported, it is the number of activated mast cells that are important and better markers of activation would be useful rather than the current gold standard of electron microscopy, which is expensive and time-consuming.
4. Finally, the release of mediators from biopsies does not link well to symptoms or mast cell numbers. The dominant factor for release is likely to be crushing and tissue injury by the biopsy process, which is not well standardised and may overwhelm other factors that would be of more interest. We need a better way of assessing in vivo activity of the mucosal cells.
Chapter 9  Conclusions

This randomised placebo-controlled trial in 115 unselected patients with IBS-D showed that mesalazine 4 g per day was no better than placebo in relieving the symptoms of abdominal pain or disturbed bowel habit. However, contrary to the previous report in just 10 patients, mesalazine did not reduce mast cell percentage area stained. Further post hoc analysis showed that raised calprotectin level was associated with less psychological distress, implying a more gut-centred abnormality. A small subgroup of patients with PI-IBS appeared to benefit but a larger adequately powered study is required to confirm this finding.

Further phenotyping of the heterogeneous group of patients with IBS-D is needed to allow better evaluation of new treatments.
Acknowledgements

Contributions of authors

Ching Lam (clinical research fellow/trial manager): managed, overall, the running of the whole trial, managed the clinical trial site in Nottingham, the analysis of data and the writing of reports/abstracts.

Wei Tan (statistician): data analysis for the clinical primary outcome data.

Matthew Leighton (research manager): trial manager for initial set-up of the study.

Margaret Hastings (research nurse): study supervision and recruitment of participants into study.

Melanie Lingaya (technician): analysis and technical support.

Yirga Falcone (technician): analysis and technical support.

Xiaoying Zhou (technician): analysis and technical support.

Luting Xu (research fellow): analysis and technical support.

Peter Whorwell (principal investigator): study concept and design.

Andrew F Walls (reader in immunopharmacology): analysis and technical support.

Abed Zaitoun (consultant histopathologist): analysis and technical support.

Alan Montgomery (senior statistician): statistical analysis and interpretation of data.

Robin C Spiller (chief investigator and senior author): obtained funding, study concept and design, interpretation of data, study supervision, recruitment.
We would like to thank:

1. The Clinical Research Network (CLRN) in assisting with the set-up of study in other centres and providing research nurses to assist in this study.
2. The PCRN who assisted with identifying potential patients with IBS in primary care.
3. Ferring Pharmaceuticals for sponsoring mesalazine and the placebo medication.
4. The CTU, University of Nottingham, for its information technology/electronic database support.
5. Nurses and technicians from the NIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust, for assisting and supporting this study.
6. Dr Andrew F Walls, Xiaoying Zhou and Laurie Lau from the Immunopharmacology Group, University of Southampton, who helped in processing the biopsy supernatants for tryptase, histamine, CPA3 and chymase.
7. Dr Abed Zaitoun and the histopathology/immunohistochemistry laboratory in the Nottingham University Hospitals NHS Trust, who helped with preparation of biopsy samples for histology/immunochemistry stains.
8. All participating principal investigators and CLRN nurses who have assisted in the recruitment and running of this study in other sites:
   - (a) Dr Jessica Williams, Gastroenterology, Royal Derby Hospitals NHS Foundation Trust
   - (b) Dr Stephen Foley, Gastroenterology, King’s Mill Hospital
   - (c) Dr Anurag Agrawal, Gastroenterology, Doncaster Royal Infirmary
   - (d) Dr Sandip Sen, Gastroenterology, United Hospitals North Staffordshire
   - (e) Dr Matthew Rutter, Gastroenterology, University Hospital of North Tees
   - (f) Dr Arvind Ramadas, Gastroenterology, James Cook University Hospital
   - (g) Professor Peter Whorwell, Neurogastroenterology Unit, University Hospital of South Manchester NHS Foundation Trust.

Publication


Notes

This study was accepted as an oral presentation in the Digestive Disease Week 2014 in Chicago, IL, USA. See Appendix 3 for abstract.
References


25. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. *Gut* 2002;51:536–9. http://dx.doi.org/10.1136/gut.51.4.536


Appendix 1 Excluded medication and dose-controlled medication

Please use in conjunction with the exclusion criteria definition.

Excluded medication

Non-steroidal anti-inflammatory drugs
Aceclofenac.
Acemetacin.
Aspirin.
Azapropazone.
Celecoxib.
Dexibuprofen.
Dexketoprofen.
Diclofenac sodium.
Etodolac.
Etoricoxib.
Fenbufen.
Fenoprofen.
Flurbiprofen.
Ibuprofen.
Indomethacin.
Ketoprofen.
Mefenamic acid.
Meloxicam.
Nabumetone.
Naproxen.
Piroxicam.
Sulindac.

Tenoxicam.

Tiaprofenic acid.

**Long-term antibiotic drugs**

Please refer to the latest version of the *British National Formulary*.

**Antispasmodic drugs**

Alverine citrate.

Mebeverine hydrochloride.

Peppermint oil.

**Antimuscarinic drugs**

Atropine sulphate.

Dicycloverine hydrochloride.

Hyoscine butylbromide.

Propantheline bromide.

**Opiates/antidiarrhoeal drugs**

Codeine.

Loperamide.

Morphine.

**Anti-inflammatory drugs**

Prednisolone.

Budesonide.

Hydrocortisone.

Azathioprine.

Mercaptopurine.

**5-aminosalicylic acid-containing medication**

Balsalazide disodium.

Mesalazine.

Olsalazine sodium.

Sulfasalazine.
Dose-controlled medication

**Selective serotonin reuptake inhibitors**
Citalopram.

Escitalopram.

Fluoxetine.

Fluvoxamine maleate.

Paroxetine.

Sertraline.

**Tricyclic antidepressant drugs**
Amitriptyline hydrochloride.

Clomipramine hydrochloride.

Dosulepin hydrochloride.

Doxepin.

Imipramine hydrochloride.

Lofepramine.

Nortriptyline.

Trimipramine.
Appendix 2 Supplementary data

Methodology for immunohistochemical staining of cells for mast cell tryptase, CD3\(^+\) T lymphocytes, CD68 and serotonin

Biopsies were formalin fixed and embedded in wax prior to standard sectioning for staining.

**TABLE 14 Summary of antibodies used in immunohistochemistry**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Supplier (order code)</th>
<th>Dilution</th>
<th>Pretreatment</th>
</tr>
</thead>
</table>
| Mast cell tryptase| Dako (M7052)          | 1/500    | • Protease 1–4 minutes  
|                   |                       |          | • Primary antibody for 32 minutes  
|                   |                       |          | • Roche ultraView detection kit\(^a\) plus Amplification kit |
| CD3               | Leica (NCL-L-CD3–565) | 1/50     | • SCC1 (EDTA-based buffer) for 64 minutes  
|                   |                       |          | • Primary antibody for 32 minutes  
|                   |                       |          | • Roche ultraView detection kit\(^a\) plus Amplification kit |
| CD68              | Dako (M0814)          | 1/2000   | • SCC1 for 64 minutes  
|                   |                       |          | • Primary antibody for 32 minutes  
|                   |                       |          | • Roche ultraView detection\(^a\) |
| 5-HT              | Dako (M0758)          | 1/400    | • Protease 1 for 4 minutes  
|                   |                       |          | • Primary antibody for 32 minutes  
|                   |                       |          | • Roche ultraView detection\(^a\) |

EDTA, ethylenediaminetetraacetic acid.  
\(^a\) Roche Diagnostics, Basel, Switzerland.

The slides prepared were scanned into the computer using the nanozoomer and was magnified ×40 for ease of portability. Cell counting was performed by a single person (LTX, fellow from the FRAME Laboratory, University of Nottingham) who was blinded to the study. Detection of each stained cell type was checked for reproducibility (> 95%) before cell counting began. At least 5–10 areas around lamina propria were drawn, and CD68 cells were counted, giving an average cell number per mm\(^2\). CD3, which is a marker of lymphocytes, was assessed by counting the number of stained cells at the superficial epithelium per area drawn (mm\(^2\)) and an average obtained. The 5-HT cells were counted at the deep lamina propria and an average of number of cells/mm\(^2\) were obtained. Mast cell tryptase expression was detected in the lamina propria using automatic software (i-Tem Desktop, Olympus Soft Imaging Solutions GMBH, Münster, Germany), as some mast cells may be in a degranulated state, thus making cell counting difficult. Results were presented as the percentage area stained for mast cell tryptase.

Mast cell proteases (tryptase, chymase and CPA3) were measured by sandwich ELISA assays developed by the Immunopharmacology Group, University of Southampton, as described previously.\(^{58–60}\) Briefly, antibodies specific for tryptase (EAR), chymase (CC2) and CPA3 (CA2) were coated on Costar™ 96-well EIA/RIA Plates (Fisher Scientific, Loughborough, UK) for 16 hours at +4 °C. Plates were washed three times and blocked with 2% bovine serum albumin (BSA) for 1 hour at room temperature and samples or protein standards of tryptase, chymase or CPA3 were added for 90 minutes. After a further washing stage, detecting antibodies that were specific for tryptase (AA5), chymase (CC2) or CPA3 (CA5) were added, the plates again washed, avidin–horseradish peroxidase added and cleavage of TMB substrate (3,3′,5,5′-tetramethylbenzidine, Sigma-Aldrich, Gillingham, UK), measured colorimetrically at 450 nm. Prior to assays being performed, the ELISA were validated for use with cell supernatants, by measuring recovery of each of the proteases spiked into samples prior. Histamine (Life Science Format) was measured using a commercially available enzyme immunoassay kit (ELISA, Neogen, Lexington, KY, USA). All assays were performed blind.
**Adverse events**

**TABLE 15  Adverse events following randomisation**

<table>
<thead>
<tr>
<th>AE</th>
<th>Mesalazine, n</th>
<th>Placebo, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exacerbation of IBS (worsening abdominal pain and or diarrhoea)</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Bloating</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Chest pain</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Discoloured urine</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Pregnant</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Flu-like illness</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

*a Mesalazine slow-release granule formulation (2 g; PENTASA®, Ferring Pharmaceuticals Ltd).*

**Recruitment**

Recruitment was slow initially owing to other staff seeing patients and not being aware of the study. The multiple visits were a deterrent and many patients said that they could not take time off work. We advertised widely. Advertising on the local buses produced no volunteers but advertising in local free papers produced a better response.
<table>
<thead>
<tr>
<th>Year</th>
<th>April</th>
<th>May</th>
<th>June</th>
<th>July</th>
<th>August</th>
<th>September</th>
<th>October</th>
<th>November</th>
<th>December</th>
<th>January</th>
<th>February</th>
<th>March</th>
<th>April</th>
<th>May</th>
<th>June</th>
<th>July</th>
<th>August</th>
<th>September</th>
<th>October</th>
<th>November</th>
<th>December</th>
<th>January</th>
<th>February</th>
<th>March</th>
<th>April</th>
<th>May</th>
<th>June</th>
<th>July</th>
<th>August</th>
</tr>
</thead>
</table>
FIGURE 19 Total recruitment by date.
<table>
<thead>
<tr>
<th>Site</th>
<th>January</th>
<th>February</th>
<th>March</th>
<th>April</th>
<th>May</th>
<th>June</th>
<th>July</th>
<th>August</th>
<th>September</th>
<th>October</th>
<th>November</th>
<th>December</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2012</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nottingham</td>
<td>15</td>
<td>16</td>
<td>21</td>
<td>21</td>
<td>24</td>
<td>30</td>
<td>33</td>
<td>37</td>
<td>40</td>
<td>43</td>
<td>55</td>
<td>57</td>
<td>24</td>
</tr>
<tr>
<td>Manchester</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>7</td>
<td>9</td>
<td>10</td>
<td>16</td>
<td>18</td>
<td>19</td>
<td>20</td>
<td>21</td>
<td>21</td>
<td>27</td>
</tr>
<tr>
<td>Derby</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Mansfield</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Doncaster</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Stoke-on-Trent</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>South Tees</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>North Tees</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>24</td>
<td>27</td>
<td>32</td>
<td>33</td>
<td>37</td>
<td>46</td>
<td>50</td>
<td>61</td>
<td>68</td>
<td>74</td>
<td>91</td>
<td>95</td>
<td>136</td>
</tr>
</tbody>
</table>

**TABLE 17** Recruitment for each site (*n*)
FIGURE 20 Recruitment by site and date.
Appendix 3 Abstract of oral presentation


A Multi-Centre, Parallel Group, Randomised Placebo Controlled Trial of Mesalazine for Treatment of Diarrhoea-Predominant Irritable Bowel Syndrome (IBS-D)

Ching Lam, Wei Tan, Matthew Leighton, Jessica Williams, Anurag Agrawal, Sandip Sen, Stephen Foley, Matt Rutter, Arvind Ramadas, Peter J. Whorwell, Alan Montgomery, Robin C. Spiller

Introduction: Irritable bowel syndrome with diarrhoea is a common outcome after inflammation due to bacterial gastroenteritis. Several studies have shown on going immune activation in the mucosa of IBS-D patients and a number of studies have suggested that Mesalazine(M) may provide benefit including a reduction in stool frequency. Our aim was to compare the effect of M versus placebo on stool frequency, powered at 90% using 1% significance level. Secondary aims were to assess effect of M on abdominal pain, stool consistency, satisfactory and relief of IBS symptoms. Methods: Eligibility was based on a 2-week baseline stool diary with a daily stool frequency of ³3 for more than 2 days/week and stool consistency of ³25% type 5-7 and ³25% type 1-2 according to the Bristol Stool Form Scale. Baseline colonoscopy/ sigmoidoscopy was performed to exclude microscopic or inflammatory colitis. Medications that may affect the gut motility and anti-inflammatory drugs were excluded from the study. Participants were randomised using a concealed web-based system to take either 2g M/ placebo (P) for a week, increasing to 2g twice a day for the remaining 11 weeks if tolerated. All participants completed a 12-week stool diary, and Hospital and Anxiety (HADS), Patient- Health (PHQ15) and EQ-5D questionnaires at baseline and end of study. At the end of each week in the stool diary, participants were required to answer ‘yes’ or ‘no’ to the question "Have you had satisfactory relief of your IBS symptoms this week?". The primary outcome of stool frequency and other clinical outcomes were based on a stool diary completed during weeks 11-12. A satisfactory relief of IBS symptoms was defined as answering ‘yes’ to weeks 11 and 12 of the stool diary. Compliance with treatment was defined as taking ³75% of medication during the study. Participants and outcome assessors were all blinded to allocation. Results: 68 patients with IBS-D, meeting the Rome III criteria, were randomised to each
group. 20 patients withdrew from the study and 1 patient had incomplete stool diary. Mean (SD) age was 47.1(13.5) years in P and 42.6(15.2) in M. F: M ratio was similar at 40:28 in P and 42:26 in M. Treatment compliance for P and M were 59% and 58%. Analysis by intention to treat showed M did not improve bowel frequency, abdominal pain and stool consistency compared to P during the last 2 weeks. Treatment did not affect satisfactory relief of IBS symptoms, HADS, PHQ15 and EQ5D VAS scores compared to P. See Table 1 for results.

Conclusion: This large study rules out any clinically meaningful benefit or harm of M compared with P. Better understanding of the underlying disease mechanisms are needed to allow more effective targeting of treatment in these patients.

Table 1

<table>
<thead>
<tr>
<th>Mean (SD)</th>
<th>Baseline placebo (n=58)</th>
<th>Final 2 weeks placebo (n=58)</th>
<th>Baseline Mesalazine (n=57)</th>
<th>Final 2 weeks Mesalazine (n=57)</th>
<th>Between group difference at week 11-12 (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily mean stool frequency</td>
<td>3.6 (1.8)</td>
<td>2.7 (1.9)</td>
<td>3.6 (1.6)</td>
<td>2.8 (1.2)</td>
<td>0.1 (-0.33, 0.53)</td>
<td>0.658</td>
</tr>
<tr>
<td>Daily mean abdominal pain (0-10)</td>
<td>3.6 (2.0)</td>
<td>2.2 (2.1)</td>
<td>4.1 (2.2)</td>
<td>2.8 (2.1)</td>
<td>0.07 (-0.54, 0.68)</td>
<td>0.828</td>
</tr>
<tr>
<td>Mean stool consistency</td>
<td>5.6 (1.0)</td>
<td>4.7 (1.1)</td>
<td>5.4 (0.7)</td>
<td>4.7 (1.0)</td>
<td>0.13 (-0.21, 0.48)</td>
<td>0.452</td>
</tr>
<tr>
<td>No. of patient had satisfactory relief of IBS symptoms</td>
<td>0</td>
<td>24</td>
<td>0</td>
<td>25</td>
<td>1.13** (0.51, 2.47)</td>
<td>0.762</td>
</tr>
<tr>
<td>HADS score</td>
<td>8.6 (4.3)</td>
<td>6.9 (3.6)</td>
<td>9.0 (4.5)</td>
<td>7.5 (5.0)</td>
<td>0.67 (-0.38, 1.72)</td>
<td>0.21</td>
</tr>
<tr>
<td>PHQ15 score</td>
<td>13.1 (5.6)</td>
<td>9.4 (5.0)</td>
<td>12.6 (5.2)</td>
<td>10.0 (5.2)</td>
<td>0.63 (-0.93, 2.20)</td>
<td>0.428</td>
</tr>
<tr>
<td>EQ-5D VAS score</td>
<td>64.3 (20.2)</td>
<td>69.7 (18.3)</td>
<td>64.2 (20.6)</td>
<td>72.6 (19.2)</td>
<td>2.39 (-3.24, 8.02)</td>
<td>0.406</td>
</tr>
</tbody>
</table>
Appendix 4  Example of stool diary used, based on the Bristol Stool Form Scale
### IBS Daily Symptom and Stool Diary (version 2.0, 25 November 2010)

#### STOOL FORM AND TIME

(Form = score 1-7 from stool chart below; Time = time of stool)

<table>
<thead>
<tr>
<th>1st</th>
<th>2nd</th>
<th>3rd</th>
<th>4th</th>
<th>5th</th>
<th>6th</th>
<th>7th</th>
<th>8th</th>
</tr>
</thead>
<tbody>
<tr>
<td>Form</td>
<td>Time</td>
<td>Form</td>
<td>Time</td>
<td>Form</td>
<td>Time</td>
<td>Form</td>
<td>Time</td>
</tr>
</tbody>
</table>

### Score each 0-10 using the scale below

#### Abdominal Pain

0 = none
1-2 = mild
3-4 = moderate
5-7 = severe
8-10 = extremely severe

#### Urgency

0 = none
1-2 = mild
3-4 = moderate
5-7 = severe
8-10 = extremely severe

#### Bleeding

0 = none
1-2 = mild
3-4 = moderate
5-7 = severe
8-10 = extremely severe

#### Severity

0 = none
1-2 = mild
3-4 = moderate
5-7 = severe
8-10 = extremely severe

#### Score each 0-10

#### Number of stools taken today?

#### Answer the following after completion of day 7:

#### Have you had satisfactory relief of your IBS symptoms this week?

**YES** ☐ **NO** ☐
Stool diary

**TABLE 18** Summary of number of days with stool diary entered at baseline and 11–12 weeks

<table>
<thead>
<tr>
<th>Stool diary</th>
<th>Number of days with stool diary recorded, mean (SD); median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>13.9 (0.3); 14 (14–14)</td>
</tr>
<tr>
<td>11–12 weeks</td>
<td>13.8 (1.2); 14 (14–14)</td>
</tr>
</tbody>
</table>
This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.